Domenico Mavilio

Domenico Mavilio

Company: University of Milan

Job title: Associate Professor


Prof. Domenico Mavilio graduated as M.D. and completed his residency program in Internal Medicine/Respiratory Medicine at the Medical School of Genova University. He then obtained his Ph.D. in Clinical and Experimental Immunology within a joint program between the University of Genova (Italy) and the National Institutes of Health (USA). He was then appointed as Research Fellow at NIH where he spent a total of 9 years before going back to his home country where he was appointed as Principal Investigator and Head of the Unit of Clinical and Experimental Immunology (UCEI) at the Humanitas Research Hospital (Milan, Italy). He also currently serves as an Associate Professor of Translational Medicine at Medical School of Milan University.

As physician, Prof. Mavilio focuses his clinical activities on immunological disorders and hematologic malignancies. As a scientist, he handles research projects of translational medicine from the “bed-to bench” side aimed to study the pathogenesis and the cure of immunologic diseases. So far, he published 109 articles on peer reviewed scientific journals, several book chapters and received several national and international prizes. His current H Index is 31 and total number of citations is 4064 (Scopus).

Prof. Mavilio also currently serves as Adjunct Investigator at NIH and is a board member of Ph.D. Program in Immunology of Milan University. Prof. Mavilio is affiliated with several national and international scientific societies, is a member of the editorial boards of several international peer-reviewed scientific journals, deputy editor of the Journal of Leukocyte Biology and elected member of the council of the Society of Leukocyte Biology.


Live Q&A Discussion 12:20 pm

Read more

day: Day One

New Insights & Perspectives in the Use of Vδ1 Anti-Tumour Effector- Functions to Develop Alternative Protocols of Adoptive Cell Immunotherapies 11:00 am

• Vδ1 T cells are more enriched at tissue sites, represent the first gamma delta T cell subset to face the development of solid tumors and are less affected by the toxicities of tumour chemotherapy • High frequencies of Vδ1 T cells infiltrating solid tumors are associated with a better prognosis and patients’ overall survival…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.